C-Peptide Blood Test: Normal Levels, Results and Diabetes

Your doctor ordered a C-peptide test — and you are not quite sure how it differs from a regular insulin level or why a separate test is needed. C-peptide is one of the most informative markers for assessing pancreatic function: it reveals exactly how much insulin your own body is producing, even if you are already receiving insulin injections. This article explains what C-peptide is, what the reference ranges mean, and when abnormal results require action.

What Is C-Peptide and Why Is It Measured Separately from Insulin

When pancreatic beta cells synthesise insulin, they first produce a precursor molecule called proinsulin. Proinsulin is a chain made of three segments: the A-chain, the B-chain, and the C-peptide (connecting peptide) that links them. Before secretion into the bloodstream, the enzyme protease cleaves proinsulin: the A- and B-chains join via disulphide bridges to form active insulin, while C-peptide is released as a separate molecule into the circulation.

The critical property of C-peptide is that it is secreted in equimolar amounts with insulin at every pancreatic release. Measuring C-peptide therefore tells us precisely how much endogenous (self-produced) insulin the pancreas has generated.

Why not simply measure insulin? Three reasons make C-peptide the preferred marker. First: the liver extracts around 50% of insulin on first pass — peripheral blood concentrations reflect only the remainder. C-peptide is barely absorbed by the liver and is cleared more slowly, making its level more stable and a more accurate reflection of beta-cell secretory activity. Second: in patients receiving exogenous insulin injections, endogenous and injected insulin are indistinguishable — but C-peptide is purely endogenous, as synthetic insulin contains none. Third: insulin assays are subject to interference from anti-insulin antibodies, which are frequently present in type 1 diabetes.

The test is ordered for: differential diagnosis of type 1 versus type 2 diabetes; assessment of residual beta-cell function during insulin therapy; suspected insulinoma (an insulin-secreting pancreatic tumour); factitious hypoglycaemia; and monitoring after pancreatic or islet cell transplantation.

How to Prepare for a C-Peptide Test

Blood is drawn from a vein, typically in the morning. C-peptide is sensitive to food intake and other factors — accurate results depend substantially on correct preparation.

Fasting: strictly required — no food for 8–12 hours. A carbohydrate load triggers insulin and C-peptide release; eating before the test will falsely elevate the basal result.

Physical activity: avoid strenuous exercise for 24 hours beforehand. Physical stress influences counter-regulatory hormones (cortisol, adrenaline), which indirectly alter C-peptide levels.

Stimulation test: for a more complete assessment of pancreatic reserve, a glucagon stimulation test is used — C-peptide is measured before and six minutes after intravenous glucagon. Stimulated C-peptide is considerably more informative than the basal value: it reveals the maximum secretory capacity of beta cells. The test is performed in an endocrinology clinic or inpatient setting.

Medications: sulphonylureas (glibenclamide, glimepiride) stimulate insulin secretion and raise C-peptide. Exogenous insulin does not directly affect C-peptide but suppresses endogenous secretion via feedback. Clarify medication timing with your doctor before testing.

Method: immunochemiluminescence assay (ICLA) or ELISA. Results are available within 1–2 business days.

C-Peptide Normal Range: Reference Values

Basal (fasting) C-peptide reference values are the same for men and women. Minor differences between laboratories reflect different analyser generations — always use the range on your own report.

State	Basal C-Peptide	Notes
Normal (fasting)	0.9–7.1 ng/mL (298–2350 pmol/L)	Same for both sexes
After glucagon stimulation	> 1.8 ng/mL	Threshold for adequate beta-cell reserve
Type 1 diabetes at onset	< 0.2 ng/mL	Near-complete beta-cell failure
Type 2 diabetes	Normal or elevated	Depends on stage and treatment

Clinical thresholds:

• < 0.2 ng/mL — critically low: severe insulin deficiency; absolute indication for insulin therapy in diabetes.
• 0.2–0.9 ng/mL — reduced: partial beta-cell preservation or early depletion.
• 0.9–7.1 ng/mL — normal: adequate beta-cell function.
• > 7.1 ng/mL — elevated: hyperinsulinism; differential diagnosis of insulinoma, obesity, and type 2 diabetes.

Causes of Elevated C-Peptide

High C-peptide means the pancreas is producing excess insulin. Causes are varied.

Early type 2 diabetes and insulin resistance. In insulin resistance, body cells respond weakly to insulin — the pancreas compensates by increasing production. C-peptide is elevated while blood glucose may still be normal or borderline. This pre-diabetic stage, once identified, offers a window for prevention.

Obesity. Visceral fat tissue releases pro-inflammatory cytokines that impair insulin signalling. The mechanism is the same: compensatory hyperinsulinaemia with correspondingly high C-peptide.

Insulinoma. A tumour of pancreatic beta cells that autonomously secretes insulin regardless of blood glucose. Clinically it presents as fasting hypoglycaemia relieved by eating sugar. C-peptide is significantly elevated simultaneously with hypoglycaemia — this is the key diagnostic pattern. When insulinoma is suspected, insulin and C-peptide are always measured during the hypoglycaemic episode.

Sulphonylurea medications. Patients taking these drugs will have elevated C-peptide — an expected pharmacological effect, not a pathological finding.

Gestational diabetes. In gestational diabetes, placental hormone-driven insulin resistance triggers compensatory C-peptide elevation. Monitoring C-peptide during pregnancy helps assess whether the mother's pancreas is coping with the increased demand.

Causes of Low C-Peptide

Low C-peptide always signals inadequate beta-cell function. Clinical significance depends on the degree of reduction.

Type 1 diabetes. Autoimmune destruction of beta cells is the primary cause of critically low C-peptide. In type 1 diabetes, the immune system produces antibodies against beta cells and progressively destroys them. At disease onset, C-peptide falls below 0.2 ng/mL and becomes essentially undetectable thereafter. Measuring C-peptide allows clinicians to distinguish type 1 from type 2 diabetes — a distinction that is critical for treatment planning.

LADA (latent autoimmune diabetes in adults). A slowly progressive form of autoimmune diabetes that initially resembles type 2 clinically but has an immunological basis. C-peptide in LADA declines gradually over years — unlike the rapid fall in classic type 1 diabetes. Identifying LADA matters because these patients will ultimately require insulin therapy.

Long-standing decompensated type 2 diabetes. Chronic beta-cell overload leads to gradual depletion — C-peptide falls over the course of the disease. When C-peptide drops below 0.5 ng/mL in type 2 diabetes, oral agents lose effectiveness and insulin is needed.

Hypoglycaemia from exogenous insulin. Low C-peptide during hypoglycaemia is direct evidence that the episode was caused by exogenously administered insulin — factitious or iatrogenic — rather than insulinoma. In insulinoma, C-peptide during hypoglycaemia is invariably high.

Chronic pancreatitis and pancreatectomy. Inflammatory destruction or surgical removal of the pancreas destroys beta cells — C-peptide falls proportionally to the tissue lost.

C-Peptide in Diabetes: Practical Significance

C-peptide is one of the endocrinologist's most useful tools in diabetes care.

For differential diagnosis: C-peptide differentiates type 1 from type 2 diabetes and identifies LADA — directly influencing management. Type 1 requires insulin from day one; type 2 treatment is escalated stepwise, with insulin introduced only when oral therapy is exhausted.

For insulin timing decisions: in type 2 diabetes patients already on oral medications, a C-peptide below 0.5 ng/mL is a clear signal that the pancreatic reserve is depleted and insulin should be added.

For monitoring the honeymoon period: in newly diagnosed type 1 diabetes, a partial remission phase often follows the start of insulin therapy — C-peptide temporarily rises above zero. Monitoring C-peptide tracks the duration and end of this window.

For transplant monitoring: after pancreatic or islet cell transplantation, a rising C-peptide is the first sign of graft survival and functional recovery.

When to See a Doctor

Prompt endocrinology consultation is warranted when:

• C-peptide is below 0.2 ng/mL — especially in young, non-obese patients: type 1 diabetes or LADA is likely, requiring immediate insulin therapy.
• High C-peptide is accompanied by episodes of loss of consciousness, sweating, or tremor when fasting — insulinoma is possible; urgent evaluation with pancreatic MRI is needed.
• In type 2 diabetes, C-peptide is declining progressively on oral therapy — an indication to reassess treatment and likely initiate insulin.
• C-peptide is markedly elevated alongside normal or low blood glucose — the classic pattern of insulinoma, requiring further investigation.
• In prediabetes, C-peptide is above normal — a sign of active insulin resistance; timely lifestyle intervention can prevent progression to full type 2 diabetes.

This article is for informational purposes only and does not replace medical consultation. Result interpretation and diagnosis are made by a qualified physician.